ABXL Market Analysis

News & Sentiment

47 articles · sorted by date
Page 1 of 3 · 47 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratio
EPS (TTM)0.0% YoY
Profit margin0.0%NONE
Market cap

Valuation

Forward P/E
PEG ratio
P/B
P/S (TTM)
EV/EBITDA

Profitability & growth

ROE (TTM)
0.0%
Operating margin
0.0%
Revenue growth YoY
0.0%
Dividend yield
9.5%
Beta

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About ABXL

Company profile

Abraxas BioScience (ABXL) is a pioneering biopharmaceutical firm committed to addressing critical medical needs through the development of innovative therapies. With a focus on leveraging cutting-edge technologies in drug discovery, ABXL boasts a promising pipeline of proprietary drug candidates aimed at enhancing patient outcomes in areas of high unmet medical need. The company emphasizes scientific excellence and adheres to rigorous regulatory standards, fostering collaborations with leading academic institutions and industry stakeholders to accelerate the advancement of transformative…

Classification

Sector
None
Industry
None
Exchange
NYSE
Country
USA
Currency
USD

Company profile

HQ
NONE
Latest quarter
Shares outstanding$0
52W high$25.54
52W low$22.66

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer